A new study indicates that more women can do something to protect themselves from recurrence of breast cancer.

Women whose tumors were supplied by estrogen can now take the drug tamoxifen after surgery, radiation and chemotherapy. Tamoxifen supports only for five years but after five years, it may be unsafe

Pfizer Inc. announces it has received approval from the U.S. Food and Drug Administration (FDA) to market Aromasin(R) (exemestane tablets) for treatment of postmenopausal women with estrogen-receptor positive early breast cancer.

The treatment is coupled with two-to-three years of tamoxifen, for a total of five consecutive years of hormonal therapy and adjuvant (post- tumor) removal therapy